AdaptHealth (AHCO) Scheduled to Post Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. AdaptHealth has set its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a negative net margin of 21.21% and a positive return on equity of 8.84%. The firm had revenue of $858.23 million for the quarter, compared to the consensus estimate of $825.94 million. On average, analysts expect AdaptHealth to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AdaptHealth Price Performance

AHCO stock opened at $10.26 on Monday. AdaptHealth has a one year low of $6.37 and a one year high of $15.37. The company has a debt-to-equity ratio of 1.44, a current ratio of 1.21 and a quick ratio of 1.00. The firm has a 50 day simple moving average of $10.32 and a two-hundred day simple moving average of $8.54. The stock has a market cap of $1.36 billion, a PE ratio of -1.93, a P/E/G ratio of 0.67 and a beta of 1.06.

Insider Buying and Selling at AdaptHealth

In related news, major shareholder James E. Flynn sold 182,607 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.02, for a total value of $2,012,329.14. Following the transaction, the insider now owns 11,643,769 shares of the company’s stock, valued at $128,314,334.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder James E. Flynn sold 52,487 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $10.93, for a total value of $573,682.91. Following the sale, the insider now directly owns 11,826,376 shares of the company’s stock, valued at approximately $129,262,289.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder James E. Flynn sold 182,607 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the sale, the insider now owns 11,643,769 shares in the company, valued at $128,314,334.38. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AHCO shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 price objective on shares of AdaptHealth in a report on Monday, March 4th. Jefferies Financial Group cut shares of AdaptHealth from a “buy” rating to a “hold” rating and lowered their target price for the company from $14.50 to $8.00 in a research note on Monday, January 8th. Truist Financial raised their price target on AdaptHealth from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, UBS Group lifted their price target on shares of AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $12.10.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.